Our immune systems weaken as we get older, making fewer cells that fight infection and help us recover from illness and injury. Scientists aren't completely sure why. They may have a better idea now, ...
MHRA authorization to initiate Phase 1/2 clinical trial at U.K. sites follows first U.S. patient dosing with EN-374 for treatment of X-linked chronic granulomatous disease BOSTON, December 10, ...
A new wave of gene therapy treatments offer a new lease on life for people with inherited diseases such as haemophilia. But ...
An international research team has identified a human protein, ANKLE1, as the first DNA-cutting enzyme (nuclease) in mammals ...
On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to ...
Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...
CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful ...
Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback